PPARα-dependent increase of mouse urine output by gemfibrozil and fenofibrate. (Q39130668)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

title

PPARα-dependent increase of mouse urine output by gemfibrozil and fenofibrate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

0 references

Danjun Song

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

Min Luo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

Manyun Dai

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

Shizhong Bu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

Weihua Wang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

Burong Zhang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

Frank J Gonzalez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

Aiming Liu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

publication date

6 September 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

Canadian Journal of Physiology and Pharmacology

29 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

page(s)

199-205

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

29 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Prevalence of metabolic syndrome and its association with physical capacity, disability, and self-rated health in Lifestyle Interventions and Independence for Elders Study participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Combination therapy of statins and fibrates in the management of cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Bezafibrate Improves Hypertension and Insulin Sensitivity in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: is that a latent disadvantage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARalpha null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

PPARalpha governs glycerol metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Fibrate therapy and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1139/CJPP-2016-0140

Deterioration in renal function associated with fibrate therapy.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27918198

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Gemfibrozil not fenofibrate decreases systemic glucose level via PPARα.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27918198

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Insulin resistance, glucose intolerance, and hyperinsulinemia. Hypertriglyceridemia versus hypercholesterolemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27918198

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1139/CJPP-2016-0140

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918198 AND SRC:MED&resulttype=core&format=json

29 March 2020

PubMed publication ID

27918198

1 reference